The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
Obesity is recognized as a chronic disease and public health concern globally. The primary goals of obesity treatment are to improve patients’ health outcomes and quality of life. Physicians…
Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides and alpha-glucosidase inhibitors continue to…
The landmark FDA approval of Biogen / Eisai’s aducanumab (Aduhelm) in 2021 has had a minimal effect on treatment dynamics in AD owing to the lack of reimbursement and the controversy surrounding…
Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…
Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic…
Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 703 currently available and novel biosimilar products, detailing…
In 2022, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
TNF-alpha inhibitors (e.g., Remicade, Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Key treatment goals…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and the interleukin (IL…